EPRX Reports 65% EREFS Reduction, 20-Injection Protocol Shows Fibrosis/Inflammation Improvement, Phase 2b Data Expected Q4 2026
Eupraxia Pharmaceuticals Inc. Common Stock · Now $6.86
+4.3% in 1d after detection
Post-detection moves
1h
—
1d
+4.3%
3d
+2.5%
7d
-1.5%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS